Clinical Trial Offers Clues About Why Some Metastatic Prostate Cancers Don’t Respond to Anti-Androgen Therapy

Joshi Alumkal, MD leads team to identify a gene program active in metastatic prostate cancers that failed to respond to enzalutamide treatment.